These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

470 related articles for article (PubMed ID: 15036135)

  • 21. Catalytically inactive anthrax toxin(s) are potential prophylactic agents.
    Gupta M; Alam S; Bhatnagar R
    Vaccine; 2007 Dec; 25(50):8410-9. PubMed ID: 17980467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Activity of the Bacillus anthracis 20 kDa protective antigen component.
    Hammamieh R; Ribot WJ; Abshire TG; Jett M; Ezzell J
    BMC Infect Dis; 2008 Sep; 8():124. PubMed ID: 18808698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lethal toxin actions and their consequences.
    Hanna P
    J Appl Microbiol; 1999 Aug; 87(2):285-7. PubMed ID: 10475969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Past, imminent and future human medical countermeasures for anthrax.
    Baillie LW
    J Appl Microbiol; 2006 Sep; 101(3):594-606. PubMed ID: 16907809
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mouse susceptibility to anthrax lethal toxin is influenced by genetic factors in addition to those controlling macrophage sensitivity.
    Moayeri M; Martinez NW; Wiggins J; Young HA; Leppla SH
    Infect Immun; 2004 Aug; 72(8):4439-47. PubMed ID: 15271901
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anthrax lethal toxin: a weapon of multisystem destruction.
    Agrawal A; Pulendran B
    Cell Mol Life Sci; 2004 Nov; 61(22):2859-65. PubMed ID: 15558214
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bacillus anthracis lethal toxin reduces human alveolar epithelial barrier function.
    Langer M; Duggan ES; Booth JL; Patel VI; Zander RA; Silasi-Mansat R; Ramani V; Veres TZ; Prenzler F; Sewald K; Williams DM; Coggeshall KM; Awasthi S; Lupu F; Burian D; Ballard JD; Braun A; Metcalf JP
    Infect Immun; 2012 Dec; 80(12):4374-87. PubMed ID: 23027535
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anthrax toxins: A paradigm of bacterial immune suppression.
    Baldari CT; Tonello F; Paccani SR; Montecucco C
    Trends Immunol; 2006 Sep; 27(9):434-40. PubMed ID: 16861036
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Anthrax revisited: Bacillus anthracis toxins as novel actors of immune escape?].
    Tournier JN; Quesnel-Hellmann A; Cleret A; Mathieu J; Goossens PL; Mock M; Vidal DR
    Bull Acad Natl Med; 2006 Jan; 190(1):155-63; discussion 163-7. PubMed ID: 16878452
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anthrax toxin: the long and winding road that leads to the kill.
    Abrami L; Reig N; van der Goot FG
    Trends Microbiol; 2005 Feb; 13(2):72-8. PubMed ID: 15680766
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resident CD11c+ lung cells are impaired by anthrax toxins after spore infection.
    Cleret A; Quesnel-Hellmann A; Mathieu J; Vidal D; Tournier JN
    J Infect Dis; 2006 Jul; 194(1):86-94. PubMed ID: 16741886
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of either lethal toxin or edema toxin by Bacillus anthracis is sufficient for virulence in a rabbit model of inhalational anthrax.
    Lovchik JA; Drysdale M; Koehler TM; Hutt JA; Lyons CR
    Infect Immun; 2012 Jul; 80(7):2414-25. PubMed ID: 22526673
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anthrax toxin receptor 2 mediates Bacillus anthracis killing of macrophages following spore challenge.
    Banks DJ; Barnajian M; Maldonado-Arocho FJ; Sanchez AM; Bradley KA
    Cell Microbiol; 2005 Aug; 7(8):1173-85. PubMed ID: 16008584
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening inhibitors of anthrax lethal factor.
    Tonello F; Seveso M; Marin O; Mock M; Montecucco C
    Nature; 2002 Jul; 418(6896):386. PubMed ID: 12140548
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proteomic analyses of murine macrophages treated with Bacillus anthracis lethal toxin.
    Sapra R; Gaucher SP; Lachmann JS; Buffleben GM; Chirica GS; Comer JE; Peterson JW; Chopra AK; Singh AK
    Microb Pathog; 2006; 41(4-5):157-67. PubMed ID: 16950595
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of the lower molecular capsule released from the cell surface of Bacillus anthracis on the pathogenesis of anthrax.
    Makino S; Watarai M; Cheun HI; Shirahata T; Uchida I
    J Infect Dis; 2002 Jul; 186(2):227-33. PubMed ID: 12134259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular pathogenesis of Bacillus anthracis infection.
    Little SF; Ivins BE
    Microbes Infect; 1999 Feb; 1(2):131-9. PubMed ID: 10594977
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antiplatelet activities of anthrax lethal toxin are associated with suppressed p42/44 and p38 mitogen-activated protein kinase pathways in the platelets.
    Kau JH; Sun DS; Tsai WJ; Shyu HF; Huang HH; Lin HC; Chang HH
    J Infect Dis; 2005 Oct; 192(8):1465-74. PubMed ID: 16170766
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Anthrax: early steps of the intracellular stage of infection development].
    Bakhteeva IV; Titareva GM; Kravchenko TB; Mironova RI; Noskov AN
    Mol Gen Mikrobiol Virusol; 2005; (4):3-9. PubMed ID: 16334217
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anthrax lethal and edema toxins in anthrax pathogenesis.
    Liu S; Moayeri M; Leppla SH
    Trends Microbiol; 2014 Jun; 22(6):317-25. PubMed ID: 24684968
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.